Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 10 on this page, newest registry updates first. Search checked 2026-11-08 18:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

ClinicalTrials.gov · NCT00308438 · Registry updated: 2021-05-14

Condition / research focus: Crohn's Disease
Sponsor: Shire
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2004-03-01. Completion: 2006-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (ALX-0600) (drug) — also listed as: teduglutide

Where the study takes place — 24 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Advanced Clinical Therapeutics
Tucson, Arizona, United States
Site recruitment: Not reported
Rocky Mountain Gastroenterology
Lakewood, Colorado, United States
Site recruitment: Not reported
Rx Trials
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Clinical Trials Management of Boca Raton
Boca Raton, Florida, United States
Site recruitment: Not reported
Clinical Research of West Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Venture Research
North Miami Beach, Florida, United States
Site recruitment: Not reported
Pinnacle Trials
Atlanta, Georgia, United States
Site recruitment: Not reported
Saint Joseph's Health System
Atlanta, Georgia, United States
Site recruitment: Not reported
Northwestern University School of Medicine
Chicago, Illinois, United States
Site recruitment: Not reported
University of Chicago
Chicago, Illinois, United States
Site recruitment: Not reported
University of Louisville
Louisville, Kentucky, United States
Site recruitment: Not reported
Long Island Clinical Research Associates
Great Neck, New York, United States
Site recruitment: Not reported
Asher Kornbluth, MD, PC
New York, New York, United States
Site recruitment: Not reported
Wake Research Associates
Raleigh, North Carolina, United States
Site recruitment: Not reported
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site recruitment: Not reported
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Atilla Ertan
Houston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported
McGuire DVAMC
Richmond, Virginia, United States
Site recruitment: Not reported
Dean Foundation Research Center
Madison, Wisconsin, United States
Site recruitment: Not reported
Vancouver General Hospital
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Health Sciences Center
Winnipeg, Manitoba, Canada
Site recruitment: Not reported
Queen Elizabeth II Health Sciences
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Life Screening Centres
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

ClinicalTrials.gov · NCT03571516 · Registry updated: 2021-05-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Finland · France · Italy · United Kingdom
Registry dates and results: Start: 2018-08-31. Completion: 2020-09-24 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Standard Medical Therapy (other)
Syringe (device)
Needle (device)

Where the study takes place — 8 listed sites

Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Site recruitment: Not reported
Groupe Hospitalier Pellegrin - Hôpital des Enfants
Bordeaux, Gironde, France
Site recruitment: Not reported
Hopital Jeanne de Flandre - CHRU Lille
Lille, Nord, France
Site recruitment: Not reported
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Site recruitment: Not reported
Great Ormond Street Hospital for Children
London, Greater London, United Kingdom
Site recruitment: Not reported
Royal Manchester Children's Hospital
Manchester, Greater Manchester, United Kingdom
Site recruitment: Not reported
Alder Hey Childrens Hospital
Liverpool, Merseyside, United Kingdom
Site recruitment: Not reported
Birmingham Children's Hospital
Birmingham, West Midlands, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

ClinicalTrials.gov · NCT03860688 · Registry updated: 2021-04-29

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2022-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED + glucose (drug)

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Teduglutide in Short Bowel Syndrome Patients

ClinicalTrials.gov · NCT04857801 · Registry updated: 2021-04-26

Condition / research focus: Short Bowel Syndrome
Sponsor: Medical University of Vienna
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-06-01. Completion: 2020-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

ClinicalTrials.gov · NCT04733066 · Registry updated: 2021-02-01

Condition / research focus: Short Bowel Syndrome; Intestinal Failure
Sponsor: Charite University, Berlin, Germany
Countries with listed sites: Germany
Registry dates and results: Start: 2020-09-01. Completion: 2022-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Charite University, Berlin, Germany
Berlin, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

ClinicalTrials.gov · NCT03663582 · Registry updated: 2020-08-04

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Japan
Registry dates and results: Start: 2018-07-06. Completion: 2019-08-06 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Syringe (device)
Needle (device)
Vial Adapter for Device (device)

Where the study takes place — 5 listed sites

Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Site recruitment: Not reported
Hyogo College of Medicine Hospital
Hyōgo, Japan
Site recruitment: Not reported
Tohoku University Hospital
Miyagi-Ken, Japan
Site recruitment: Not reported
Osaka University Hospital
Osaka, Japan
Site recruitment: Not reported
Yokohama Municipal Citizen's Hospital
Yokohama, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

ClinicalTrials.gov · NCT03534661 · Registry updated: 2020-03-27

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2017-09-27. Completion: 2019-03-20 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide + Normal Saline (drug) — also listed as: L-NMMA control
Teduglutide + L-NMMA (drug) — also listed as: active treatments
Placebo + L-NMMA (drug) — also listed as: Teduglutide control

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Short Bowel Syndrome and Teduglutide Versus Placebo

ClinicalTrials.gov · NCT02099084 · Registry updated: 2016-02-22

Condition / research focus: Short Bowel Syndrome
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2014-01. Completion: 2015-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex, Revestive
Placebo (drug)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

ClinicalTrials.gov · NCT01028924 · Registry updated: 2012-05-07

Condition / research focus: Healthy
Sponsor: Nycomed
Countries with listed sites: Germany
Registry dates and results: Start: 2009-11. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Nycomed GmbH
Konstanz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

ClinicalTrials.gov · NCT01028768 · Registry updated: 2012-05-07

Condition / research focus: Renal Impairment
Sponsor: Nycomed
Countries with listed sites: Germany
Registry dates and results: Start: 2009-10. Completion: 2010-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Nycomed GmbH
Konstanz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 10 on this page, newest registry updates first. Search checked 2026-11-08 18:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008

ClinicalTrials.gov · NCT00308438 · Registry updated: 2021-05-14

Condition / research focus: Crohn's Disease
Sponsor: Shire
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2004-03-01. Completion: 2006-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (ALX-0600) (drug) — also listed as: teduglutide

Where the study takes place — 24 listed sites

Advanced Clinical Therapeutics
Tucson, Arizona, United States
Site recruitment: Not reported
Rocky Mountain Gastroenterology
Lakewood, Colorado, United States
Site recruitment: Not reported
Rx Trials
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Clinical Trials Management of Boca Raton
Boca Raton, Florida, United States
Site recruitment: Not reported
Clinical Research of West Florida
Clearwater, Florida, United States
Site recruitment: Not reported
Venture Research
North Miami Beach, Florida, United States
Site recruitment: Not reported
Pinnacle Trials
Atlanta, Georgia, United States
Site recruitment: Not reported
Saint Joseph's Health System
Atlanta, Georgia, United States
Site recruitment: Not reported
Northwestern University School of Medicine
Chicago, Illinois, United States
Site recruitment: Not reported
University of Chicago
Chicago, Illinois, United States
Site recruitment: Not reported
University of Louisville
Louisville, Kentucky, United States
Site recruitment: Not reported
Long Island Clinical Research Associates
Great Neck, New York, United States
Site recruitment: Not reported
Asher Kornbluth, MD, PC
New York, New York, United States
Site recruitment: Not reported
Wake Research Associates
Raleigh, North Carolina, United States
Site recruitment: Not reported
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site recruitment: Not reported
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Atilla Ertan
Houston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported
McGuire DVAMC
Richmond, Virginia, United States
Site recruitment: Not reported
Dean Foundation Research Center
Madison, Wisconsin, United States
Site recruitment: Not reported
Vancouver General Hospital
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Health Sciences Center
Winnipeg, Manitoba, Canada
Site recruitment: Not reported
Queen Elizabeth II Health Sciences
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
Life Screening Centres
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

ClinicalTrials.gov · NCT03571516 · Registry updated: 2021-05-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Finland · France · Italy · United Kingdom
Registry dates and results: Start: 2018-08-31. Completion: 2020-09-24 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Standard Medical Therapy (other)
Syringe (device)
Needle (device)

Where the study takes place — 8 listed sites

Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Site recruitment: Not reported
Groupe Hospitalier Pellegrin - Hôpital des Enfants
Bordeaux, Gironde, France
Site recruitment: Not reported
Hopital Jeanne de Flandre - CHRU Lille
Lille, Nord, France
Site recruitment: Not reported
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Site recruitment: Not reported
Great Ormond Street Hospital for Children
London, Greater London, United Kingdom
Site recruitment: Not reported
Royal Manchester Children's Hospital
Manchester, Greater Manchester, United Kingdom
Site recruitment: Not reported
Alder Hey Childrens Hospital
Liverpool, Merseyside, United Kingdom
Site recruitment: Not reported
Birmingham Children's Hospital
Birmingham, West Midlands, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

ClinicalTrials.gov · NCT03860688 · Registry updated: 2021-04-29

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2022-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED + glucose (drug)

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Teduglutide in Short Bowel Syndrome Patients

ClinicalTrials.gov · NCT04857801 · Registry updated: 2021-04-26

Condition / research focus: Short Bowel Syndrome
Sponsor: Medical University of Vienna
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-06-01. Completion: 2020-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

ClinicalTrials.gov · NCT04733066 · Registry updated: 2021-02-01

Condition / research focus: Short Bowel Syndrome; Intestinal Failure
Sponsor: Charite University, Berlin, Germany
Countries with listed sites: Germany
Registry dates and results: Start: 2020-09-01. Completion: 2022-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Charite University, Berlin, Germany
Berlin, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

ClinicalTrials.gov · NCT03663582 · Registry updated: 2020-08-04

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Japan
Registry dates and results: Start: 2018-07-06. Completion: 2019-08-06 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Syringe (device)
Needle (device)
Vial Adapter for Device (device)

Where the study takes place — 5 listed sites

Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Site recruitment: Not reported
Hyogo College of Medicine Hospital
Hyōgo, Japan
Site recruitment: Not reported
Tohoku University Hospital
Miyagi-Ken, Japan
Site recruitment: Not reported
Osaka University Hospital
Osaka, Japan
Site recruitment: Not reported
Yokohama Municipal Citizen's Hospital
Yokohama, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

ClinicalTrials.gov · NCT03534661 · Registry updated: 2020-03-27

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2017-09-27. Completion: 2019-03-20 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide + Normal Saline (drug) — also listed as: L-NMMA control
Teduglutide + L-NMMA (drug) — also listed as: active treatments
Placebo + L-NMMA (drug) — also listed as: Teduglutide control

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Short Bowel Syndrome and Teduglutide Versus Placebo

ClinicalTrials.gov · NCT02099084 · Registry updated: 2016-02-22

Condition / research focus: Short Bowel Syndrome
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2014-01. Completion: 2015-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex, Revestive
Placebo (drug)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers

ClinicalTrials.gov · NCT01028924 · Registry updated: 2012-05-07

Condition / research focus: Healthy
Sponsor: Nycomed
Countries with listed sites: Germany
Registry dates and results: Start: 2009-11. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Nycomed GmbH
Konstanz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

ClinicalTrials.gov · NCT01028768 · Registry updated: 2012-05-07

Condition / research focus: Renal Impairment
Sponsor: Nycomed
Countries with listed sites: Germany
Registry dates and results: Start: 2009-10. Completion: 2010-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Nycomed GmbH
Konstanz, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →